



## (51) International Patent Classification:

A61K 47/68 (2017.01) A61K 31/7125 (2006.01)  
C12N 15/113 (2010.01) C07K 16/28 (2006.01)  
A61K 31/712 (2006.01)

## (21) International Application Number:

PCT/US2022/073529

## (22) International Filing Date:

08 July 2022 (08.07.2022)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

63/220,108 09 July 2021 (09.07.2021) US

(71) Applicant: DYNETHERAPEUTICS, INC. [US/US];  
1560 Trapelo Road, Waltham, MA 02451 (US).(72) Inventors: DESJARDINS, Cody, A.; 1560 Trapelo Road,  
Waltham, MA 02451 (US). TANG, Kim; 1560 Trapelo  
Road, Waltham, MA 02451 (US). MCSWIGGEN, James;  
19395 W. 94th Avenue, Arvada, CO 80007 (US). SUBRA-  
MANIAN, Romesh, R.; 9 Alan Street, Framingham, MA  
01701 (US). WEEDEN, Timothy; 1560 Trapelo Road,  
Waltham, MA 02451 (US). QATANANI, Mohammed, T.;  
1560 Trapelo Road, Waltham, MA 02451 (US). QUINN,  
Brendan; 45 East Newton Street #320, Boston, MA 02118(US). NAJIM, John; 1560 Trapelo Road, Waltham, MA  
02451 (US).(74) Agent: BUSS, Colin, G. et al.; Wolf, Greenfield & Sacks,  
P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

## (54) Title: MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES




FIG. 1

(57) Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*